To date, there are no full-length research articles describing changes in RA disease activity following treatment with GLP-1 receptor agonists, he says
It might take as short as a few day after cessation of carnitine, cardiac arrhythmia and cardiac arrest might come suddenly leading to fatal outcome.23,24 On the other hand, it is uncertain if asymptomatic carrier (with one mutation) should be treated with carnitine
Yes, some seromas recur and may need repeat aspiration or additional management, depending on the situation
Nat Med 29(10):24382457
The patent dance provisions of the BPCIA, which govern information exchange between the reference product sponsor and a biosimilar applicant after the 351(k) application is filed, create additional procedural timelines that typically add 18 to 36 months to the effective market entry date for biosimilars even after the 12-year exclusivity expires
Before adding another bottle to the shelf, it may be worth asking: "Am I addressing a real deficiency or simply following a trend?" Evidence-based healthcare starts with informed decisions, not viral recommendations
